<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337219</url>
  </required_header>
  <id_info>
    <org_study_id>RM/NEB-03-10</org_study_id>
    <nct_id>NCT01337219</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis</brief_title>
  <acronym>RM/NEB-03-10</acronym>
  <official_title>Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaide® in Patients With Cystic Fibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erempharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant (EPICIME)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clininfo S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erempharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis (CF) is a genetic disease characterized by mutations in CFTR (Cystic Fibrosis
      Transmembrane conductance Regulator) gene. Mortality and morbidity are mostly related to the
      respiratory affection which appears early in neonates.

      The constant improvement in symptomatic treatments and care strategies allowed CF patients'
      life expectancy to be increased over the last decades.

      Vital prognostic is related to bronchopulmonary infections. 39% of CF patients under 18 years
      old and 70% of adult CF patients are chronically infected by Pseudomonas aeruginosa.

      Elevated concentrations of tobramycin in broncho secretions, about 1000 times the MIC, is
      obtained by inhaled administration of tobramycin and is active against in-vitro resistant
      Pseudomonas aeruginosa.

      Study hypotheses :

      Regarding literature data and in-vitro studies, the administration of Nebcinal® 150mg/3ml
      administered twice a day by Aeroneb® Idehaler® pocket® would deliver the same quantity of
      antibiotic in lung and plasma as Tobi® 300mg/5ml administered twice a day by Pari® LC Plus®
      in children and adult patients with CF.

      Primary objective :

      To compare plasma concentrations after inhalation of Nebcinal® 150mg/3ml administered by
      Aeroneb® Idehaler pocket® and Tobi® 300 mg/5ml administered by Pari LC Plus®
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of tobramycin from 0 to 8h after administration</measure>
    <time_frame>from 0 to 8h after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sputum of tobramycin concentrations</measure>
    <time_frame>from 0 to 8 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nebcinal® 150mg/3ml administered by Aeroneb® Idehaler pocket®;</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of nebulization of Nebcinal® 150mg/3ml administered by Aeroneb® Idehaler pocket®</measure>
    <time_frame>during nebulization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of Nebcinal® 150mg/3ml administered by Aeroneb® Idehaler pocket®</measure>
    <time_frame>after administration of the drug, in average 20 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>experimental treatment (Nebcinal/Aeroneb Idehaler pocket) - 6day-wash out period - standard treatment (Tobi/Pari LC Plus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard treatment (Tobi/Pari LC Plus) - 6day-wash out period - experimental treatment (Nebcinal/Aeroneb Idehaler)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults and children aged 6 years old and more

          -  Male or female

          -  Patients with cystic fibrosis (positive sudoral test, Cl &gt; 60 mmol/L)

          -  Followed in a CRCM (CF care centre)

          -  FEV1 ≥40%

          -  Informed consent collected from adults or parents or legal guardians and children.

          -  Affiliation to the National Health Insurance program (Sécurité sociale).

        Exclusion Criteria:

          -  renal insufficiency defined by a creatinine clearance level superior to 2 mg/dl

          -  recent pneumothorax, emphysema, punction or recent pleural biopsy, recent haemoptysis
             superior to 60 ml within 30 days prior to randomization

          -  Acute pulmonary exacerbation pathology, according to conference of consensus (2002),
             evaluated by :

          -  Cough increase

          -  Sputum increase

          -  Decrease in tolerance to effort

          -  Loss of weight, lack of appetite

          -  Deterioration of respiratory function

          -  Medical history of intolerance, toxicity or allergy to tobramycin, hypersensitivity to
             aminoside
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Bellon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Resources et de competences pour la mucovisidose</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Durieu, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Resources et de competences pour la mucovisidose Hôpital Lyon Sud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>behrouz Kassai, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>University of Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Behrouz Kassaï</last_name>
    <phone>04 27857732</phone>
    <phone_ext>0033</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Paul Salin</last_name>
    <phone>0140899260</phone>
    <phone_ext>0033</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Ressource et de Compétence Mucoviscidose Pédiatrique Centre de Référence Mucoviscidose</name>
      <address>
        <city>Lyon</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Bellon, Pr</last_name>
      <phone>04 27 85 59 82</phone>
      <phone_ext>0033</phone_ext>
      <email>gabriel.bellon@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gabriel Bellon, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <last_update_submitted>April 15, 2011</last_update_submitted>
  <last_update_submitted_qc>April 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Erempharma</name_title>
    <organization>Erempharma</organization>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>sputum</keyword>
  <keyword>plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

